Background/Objectives: We aim to confirm the association between the high risk score on bispectral electroencephalogram (BSEEG) and mortality by comparing outcomes for those with "diffuse slowing" and normal findings on standard EEG.
Introduction
Delirium is defined as an acute decline in attention and either disorganized thinking or altered level of consciousness with a fluctuating course.(1) Delirium can be considered to be acute brain failure (2) and is thought to be caused by many factors, including drugs, infections, central nervous system (CNS) insults,(3) sleep disturbance,(4) metabolic disturbances(5), and pain. (6) Advanced age and comorbidities predispose patients to developing delirium following any of the above insults.(7) (8) Delirium is very common in older patients, complicating about a third of hospital stays and often persists following discharge.(9, 10) Moreover, it is associated with higher morality and worse functional outcomes.(11) Thus, identification of delirious patients to initiate treatment for potentially reversible causes is vital to improve patient outcomes.
Delirium is typically identified by clinical assessment using the Confusion Assessment Method (CAM)(12) or similar questionnaire style instruments meant particularly for settings such as the intensive care unit (CAM-ICU).(13) However, it is frequently underdiagnosed in the hospital because of its often subtle and varied presentations; agitated, hyperactive delirium represents the minority of cases while mixed and hypoactive delirium are more common.(9) Reliable biomarkers of delirium are therefore desirable and needed for better patient care. Electrophysiological brain signals are a well-known biomarker, with a specificity of 91% in one study of patients with dementia.
(2) In that study, electroencephalogram (EEG) had a low sensitivity but another study with a more general population found that 96% (50/52) of those with encephalopathy have "background slowing" indicating that EEG signals read by neurology experts as "diffuse slowing" is a sensitive marker for encephalopathy. (14) At 1 year, 15/119 (12.6%) with normal EEG had died, 41/145 (28.2%) of those with focal findings without diffuse slowing or ictal findings, 138/372 (37.1%) of those with diffuse slowing without focal or ictal findings, 122/291 (42.0%) of those with diffuse slowing, a focal finding or lateralization and no ictal finding, and 32/75 (42.7%) of those with ictal findings died. Mortality at earlier time intervals is visualized with a survival curve, Figure 1 , which also displays the number at risk at intervals of 60 days.
At 1 year, all groups with abnormal findings appear to do worse than those with normal findings (salmon-colored), with ictal and diffuse slowing apparently similar to one another (teal, blue, and violet) , and worse than those with only focal findings (yellow). These differences are significant controlling for age, sex, and CCI except that the difference between the diffuse slowing nonfocal group is not significantly worse than the focal only group (P =0.148), as shown in Table 1 .
Diffuse Slowing Analysis
Because the two diffuse slowing groups were similar, we combined the two for further analysis of mortality and secondary outcomes. We stratified the combined diffuse slowing group by clinical status into two groups: those whose status included "awake" during EEG recording and those whose status did not. The survival curve shown in Figure 2 shows the difference from normals is retained in the awake group and shows a worse outcome among those with diffuse slowing who were not awake. Multivariate regressions controlling for age, sex, and CCI confirm that the difference between the awake group and normals is significant at 90 days and beyond. Table 2 shows results of statistical analysis for mortality outcomes as well as secondary outcomes, which were also significant. The other group is significantly different from both normals and from the awake group (P values listed in Table 2 are those for difference from the awake group).
Discussion
Continuous EEG (cEEG) monitoring is reportedly used in close to 1/100 mechanically ventilated patients based on a study from 2008(23) but likely is more common, with another study finding a 10-fold increase from 2004 to 2013. (24) Continuous EEG offers much better detection of seizure than routine EEG, (25, 26) which is important because mortality is much higher in nonconvulsive seizures (32-51%), than in those without (13%).(27) While one study did not show better discharge Glasgow Coma Scale (GCS) score in those who received cEEG compared to those who did not, the study did note a difference in GCS at admission, which is consistent with an improvement related to EEG use although such a retrospective study does not allow for inference of causation.(28) Other studies do show differences in in-hospital mortality(23, 27) with use of cEEG, and a randomized control study investigating differences in 6-month mortality between use of routine and continuous EEG is underway. (29) While investigation for seizure is often the stated indication for a continuous EEG study(30) "diffuse slowing" is a common finding and may be given less attention than needed. In our retrospective study of standard, 24-hour EEG reports in 1069 inpatients, we found that "diffuse slowing" on cEEG is significantly associated with mortality after an adjustment for age, sex, and CCI, confirming previous associations between diffuse slowing on EEG and mortality.(31, 32) In addition, we demonstrated the association persists even when limited to awake patients only.
Our results also indicated that the mortality among the group with "diffuse slowing" is as bad as . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. not peer-reviewed) that among those with seizure and is worse than those with only focal findings. That the association becomes significant at 90 days and continues to 1 year in awake patients suggests that diffuse slowing is not necessarily an acute process which resolves but may be a marker of a more continual effect beyond its occurrence during hospitalization. Diffuse slowing may be important to screen for beyond its usual identification as an incidental finding in those evaluated for seizures. Our study therefore confirms the importance of previously mentioned association between bispectral EEG and mortality. (19) Indications for EEG and frequency of outcomes were comparable to a large, three center study.(33) In this study 75.1% or orders were for underlying seizures while in that study 72.5%-70% of indications were for nonconvulsive seizures. There were also similar rates of seizures, with this study finding seizures at a rate of 7.0% using the first 24 hours of continuous EEG while that study found seizures at a rate of 12.9% over multiple day recordings, stating around 87.2% of seizures were found in the first day for a 24-hr rate of 11.2%. The difference may be due to physician ordering patterns.
There were several limitations to the study. The first of which is a feature of the finding of diffuse slowing itself. Anesthetic agents are very common and can cause diffuse slowing on EEG. However, we did not collect data on the use of anesthetic agents such as propofol or benzodiazepines or excluding subjects receiving anesthetic agents because doing so would likely eliminate many who had diffuse slowing for some other reason, or whose slowing was multiplydetermined. Our study of awake patients mitigates that problem to some extent, as awake . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. not peer-reviewed) patients are less likely to have received sedatives, and we can be more confident that those in that group had a finding of diffuse slowing for some other reasons.
Other limitations relate to the generalizability of the study and to treatment applications. The study was performed at a single center. EEGs used in this study were not ordered at a standardized time or for a standardized indication, and results may have been affected by different ordering habits of treating physicians. This study did not include outpatients and the finding of diffuse slowing may not be associated with mortality in that population. This study did not determine the meaning of diffuse slowing in biological, biochemical, or anatomical terms. This study did not compare other potential factors influencing EEG findings such as specific medical/neurological conditions, medications, or interventions they received following EEG findings, although inclusion of CCI was meant to help control for comorbidity factors. CCI is limited in that it does not distinguish between conditions occurring before admission or during admission so it is unclear if or how they affected the use of EEG. We did not compare patients who didn't receive EEGs and/or those who received only routine EEGs. This study does not demonstrate that identifying diffuse slowing or other abnormal findings leads to changes in management or outcomes.
Conclusion
Our findings show that an EEG finding of "diffuse slowing" in the inpatient setting for patients 55 year or older is associated with greater mortality, in fact similar to mortality found in those with seizures. Our study suggests that the finding of diffuse slowing on EEG, which is a characteristic EEG feature for delirium, is an important clinical marker for predicting mortality . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. not peer-reviewed) (which was The copyright holder for this preprint . http://dx.doi.org/10.1101/19009621 doi: medRxiv preprint first posted online Oct. 22, 2019 ;  and therefore bispectral EEG may become a useful screening tool for elderly patients if identification of diffuse slowing can lead to better outcomes.
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